Evidence map›Paper›PMID 32436945›Full record

ArticleBioscience reports2020

A three-gene signature might predict prognosis in patients with acute myeloid leukemia.

Xin Zhu, Qian Zhao, Xiaoyu Su, Jinming Ke, Yunyun Yi, Jing Yi, Jiang Lin, Jun Qian, Zhaoqun Deng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Biomedicines · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xin ZhuDepartment of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, People's Republic of China.
Qian ZhaoDepartment of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, People's Republic of China.
Xiaoyu SuDepartment of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, People's Republic of China.
Jinming KeFaculty of Forestry, Zhejiang A&F University, Hangzhou 310020, Zhejiang, People's Republic of China.
Yunyun YiDepartment of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, People's Republic of China.
Jing YiDepartment of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, People's Republic of China.
Jiang LinDepartment of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, People's Republic of China.
Jun QianDepartment of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, People's Republic of China.
Zhaoqun DengDepartment of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, People's Republic of China.
Jiangsu University · CNZhejiang A & F University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of effective signatures is crucial to predict the prognosis of acute myeloid leukemia (AML). The investigation aimed to identify a new signature for AML prognostic prediction by using the three-gene expression (octamer-binding transcription factor 4 (OCT4), POU domain type 5 transcription factor 1B (POU5F1B) and B-cell-specific Moloney murine leukemia virus integration site-1 pseudogene 1 (BMI1P1). The expressions of genes were obtained from our previous study. Only the specimens in which three genes were all expressed were included in this research. A three-gene signature was constructed by the multivariate Cox regression analyses to divide patients into high-risk and low-risk groups. Receiver operating characteristic (ROC) analysis of the three-gene signature (area under ROC curve (AUC) = 0.901, 95% CI: 0.821-0.981, P<0.001) indicated that it was a more valuable signature for distinguishing between patients and controls than any of the three genes. Moreover, white blood cells (WBCs, P=0.004), platelets (PLTs, P=0.017), percentage of blasts in bone marrow (BM) (P=0.011) and complete remission (CR, P=0.027) had significant differences between two groups. Furthermore, high-risk group had shorter leukemia-free survival (LFS) and overall survival (OS) than low-risk group (P=0.026; P=0.006), and the three-gene signature was a prognostic factor. Our three-gene signature for prognosis prediction in AML may serve as a prognostic biomarker.

Indexed as

Gene Expression ProfilingPseudogenesTranscriptomeAdultAgedAged, 80 and overBiomarkers, TumorCase-Control StudiesDisease-Free SurvivalFemaleHomeodomain ProteinsHumansLeukemia, Myeloid, AcuteMaleMiddle AgedOctamer Transcription Factor-3Biomarkers, TumorBMI1 protein, humanHomeodomain ProteinsOctamer Transcription Factor-3Polycomb Repressive Complex 1POU5F1B protein, humanPOU5F1 protein, humanAcute Myeloid Leukemia (AML)BiomarkerGene SignaturePrognosis

Identifiers

PMID32436945
PMCPMC7269913
OpenAlexW3027775045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.